Latest Media Releases (Page 13) | Finance News Network

Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SUDA Pharmaceuticals European Anagrelide Cancer Patent (ASX:ALA)

Key Points: Anagrelide is an FDA approved drug for blood disorders Strong scientific rationale for its use in cancer SUDA has global IP rights across multiple delivery systems EU patent offi...read more

AusCann Announces New Supply Agreement with TasAlk (ASX:AC8)

Highlights New agreement with TasAlk secures the supply of high-quality cannabis resin to AusCann Resin supply to be used for future production and development of AusCann’s cannabi...read more

SUDA Pharmaceuticals supplementary prospectus (ASX:ALA)

To view the supplementary prospectus, download the attached PDF.

SUDA Pharmaceuticals Rights Issue Closes Significantly Oversubscribed (ASX:ALA)

Key points: Renounceable rights offer closes oversubscribed with proceeds of $3.44m Additional placement of $0.46m (total proceeds $3.9m) For more information, download the attached PDF. &...read more

SUDA Pharmaceuticals rights issue to raise $3.44 million (ASX:ALA)

1 for 3 renounceable rights issue to raise up to $3.44 million Attractively priced at 0.4 cents per share Partially underwritten to $1.0 million Discount of 38% ...read more

Suda Pharmaceutical's Prospectus (ASX:ALA)

Prospectus for a renounceable pro rata offer to Eligible Shareholders of approximately 860,653,044 New Shares at an issue price of $0.004 per New Share on the basis of 1 New Share for every three ...read more

SUDA Pharmaceuticals Product Development Market Update (ASX:ALA)

Key points: 505(b)(2) abbreviated pathway requires significantly less time and lower investments in direct research and development expenditures SUDA prioritising its internal develo...read more

SUDA Pharmaceuticals Appendix 4C: Q3 FY2019 (ASX:ALA)

SUDA Pharmaceuticals Ltd (ASX:SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4C for the consolidated Group for the third quarter of FY2019. For more information, downl...read more

SomnoMed Announces Core Revenue Growth up 9% in Q3 (ASX:SOM)

29th April 2019, SomnoMed Limited (ASX:SOM) announced that its core revenues grew by 9% in the third quarter compared to the prior year, reaching $14.3 million for the three month period. APAC deliver...read more

Suda Pharmaceuticals trading halt (ASX:ALA)

For more information, download the attached PDF.

AusCann, Appendix 4D and Half Year Financial Report, 31 December 2018 (ASX:AC8)

TABLE OF CONTENTS - DIRECTORS’ REPORT - AUDITOR’S INDEPENDENCE DECLARATION - CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME - CONSOLIDATED STATEMENT OF...read more

AusCann Announces Experienced Global Pharmaceutical Executive Appointed as new CEO (ASX:AC8)

25 February 2019 – The Board of leading medicinal cannabis company AusCann Group Holdings Limited (ASX:AC8) (‘AusCann’ or ‘the Company’) is pleased to announce the appoin...read more

AusCann Announces Cannabis Resin Supply Agreement Signed with Canadian MediPharm Labs (ASX:AC8)

21 February 2019 – Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (‘AusCann’ or ‘the Company’) is pleased to announce it has entered into a Sup...read more

SomnoMed, Investor Presentation, Half Year FY2019 (ASX:SOM)

Outline 1. First-half results summary 2. Vision & market opportunity 3. Financial information 4. Outlook To view Presentation please download PDF attached:

SUDA Pharmaceuticals Appendix 4C amended (ASX:ALA)

SUDA Pharmaceuticals Ltd (ASX:SUD), a leader in oro-mucosal drug delivery, released an amended Appendix 4C which had been released 31 January 2019. For more information, download the atta...read more

Viewing: 181 - 195 of 200 Previous | Next